THE Therapeutic Goods
Administration has designated
elosulfase-alpha, sponsored by
BioMarin Pharmaceutical Australia
Pty Ltd, as a new orphan drug.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 15 Jul 13 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jul 13
AUSTRALIAN Pharmaceutical Industries has refined tactical sales activity and continues to develop exclusive products and range extensions, as part of a strategy to combat weak consumer demand which saw the company report a 24.9% decline in H1 net profit to $24.9 million (PD breaking news).